SCHEMBL929550

SCHEMBL929550

CC(C)(S)CC(=O)NCCCS

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CASP2 P42575 1/20 0.34
TSHR P16473 1/20 0.33
HDAC6 Q9UBN7 7/20 0.33
HDAC1 Q13547 6/20 0.33
HDAC10 Q969S8 6/20 0.33
HDAC2 Q92769 5/20 0.33
HDAC8 Q9BY41 5/20 0.33
HDAC3 O15379 4/20 0.33
HDAC11 Q96DB2 4/20 0.33
HDAC4 P56524 3/20 0.33
HDAC7 Q8WUI4 3/20 0.33
HDAC9 Q9UKV0 3/20 0.33
HDAC5 Q9UQL6 3/20 0.33
DNM1 Q05193 1/20 0.33
NAAA Q02083 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL930393 0.94 MEN1 (0.43) MEN1KMT2AALDH1A1SMN1; SMN2CASP2
SCHEMBL931025 0.88 HDAC3 (0.38) MEN1KMT2AHDAC6HDAC1HDAC10
SCHEMBL14179007 0.81 FFAR1 (0.44) MEN1KMT2AALDH1A1SMN1; SMN2TSHR
SCHEMBL20417364 0.81 CASP2 (0.58) MEN1KMT2ACASP2NAAA
SCHEMBL929623 0.79 HPGD (0.32) RECQL
SCHEMBL20734738 0.76 ECE1 (0.48) MEN1KMT2ATSHRCNR1
SCHEMBL928969 0.75 POLB (0.41) MEN1KMT2AALDH1A1SMN1; SMN2HDAC6
SCHEMBL8956745 0.75 MEN1 (0.43) MEN1KMT2AALDH1A1SMN1; SMN2CASP2
SCHEMBL19432365 0.74 TSHR (0.33) MEN1KMT2AALDH1A1SMN1; SMN2TSHR
SCHEMBL22900019 0.74 MCL1 (0.41) MEN1KMT2AALDH1A1SMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875268-B2 The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves L'OREAL S.A. (FR) 2011-01-25 US claimed
EP-1584615-B1 Use of dimercaptoamides for permanently deforming of keratinic fibres OREAL (FR) 2008-05-28 EP claimed
US-20060013784-A1 Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith L'OREAL S.A. (FR) 2006-01-19 US claimed
EP-1584615-A1 Use of dimercaptoamides for permanently deforming of keratinic fibres L'OREAL (FR) 2005-10-12 EP claimed
US-10675842-B2 Transparent electrode and organic electronic device including the same Konica Minolta, Inc. (JP) 2020-06-09 US disclosed
US-20190047258-A1 TRANSPARENT ELECTRODE AND ORGANIC ELECTRONIC DEVICE INCLUDING THE SAME MERCK PATENT GMBH (DE) 2019-02-14 US disclosed
US-7875268-B2 The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves L'OREAL S.A. (FR) 2011-01-25 US disclosed
EP-1584615-B1 Use of dimercaptoamides for permanently deforming of keratinic fibres OREAL (FR) 2008-05-28 EP disclosed
US-20060013784-A1 Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith L'OREAL S.A. (FR) 2006-01-19 US disclosed
EP-1584615-A1 Use of dimercaptoamides for permanently deforming of keratinic fibres L'OREAL (FR) 2005-10-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060013784-A1 Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith KRT18, CKAP4, S100A4 MEN1 3938/4885KMT2A 1387/4885ALDH1A1 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.